These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8904115)

  • 1. Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa.
    Giacometti A; Del Prete MS; Cirioni O; Izat MK; Balducci M; Cesarini AM; Scalise G
    J Chemother; 1995 Nov; 7 Suppl 4():76-7. PubMed ID: 8904115
    [No Abstract]   [Full Text] [Related]  

  • 2. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem: morphological changes and lethal effects on Pseudomonas aeruginosa.
    Carlone NA; Ferrero M; Cuffini AM; Cavallo R
    Drugs Exp Clin Res; 1987; 13(10):623-9. PubMed ID: 3123190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of imipenem/EDTA combined disc and Etest for detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Bergès L; Rodriguez-Villalobos H; Deplano A; Struelens MJ
    J Antimicrob Chemother; 2007 Apr; 59(4):812-3. PubMed ID: 17317694
    [No Abstract]   [Full Text] [Related]  

  • 5. Beta-lactamase induction and aminoglycoside susceptibility in Pseudomonas aeruginosa.
    Stratton CW; Weeks LS; Tausk F
    J Antimicrob Chemother; 1987 Jan; 19(1):21-5. PubMed ID: 3104276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem.
    Farra A; Islam S; Strålfors A; Sörberg M; Wretlind B
    Int J Antimicrob Agents; 2008 May; 31(5):427-33. PubMed ID: 18375104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silent spread of IMP-13-producing Pseudomonas aeruginosa belonging to sequence type 621 in Belgium.
    Naas T; Bogaerts P; Kostyanev T; Cuzon G; Huang TD; Ozsu S; Nordmann P; Glupczynski Y
    J Antimicrob Chemother; 2011 Sep; 66(9):2178-9. PubMed ID: 21693463
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of multi and pan drug resistant Pseudomonas aeruginosa with respect to ESBL and MBL in a tertiary care hospital.
    Jayakumar S; Appalaraju B
    Indian J Pathol Microbiol; 2007 Oct; 50(4):922-5. PubMed ID: 18306607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18.
    Hanson ND; Hossain A; Buck L; Moland ES; Thomson KS
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2272-3. PubMed ID: 16723605
    [No Abstract]   [Full Text] [Related]  

  • 10. First report of the carbapenem-resistant Pseudomonas aeruginosa producing IMP-7 metallo-beta-lactamase in Slovakia.
    Ohlasova D; Kmet V; Niks M
    Int J Antimicrob Agents; 2007 Oct; 30(4):370-1. PubMed ID: 17709230
    [No Abstract]   [Full Text] [Related]  

  • 11. Imipenem and meropenem induced resistance to beta-lactam antibiotics in Pseudomonas aeruginosa.
    Giacometti A; Siquini FM; Cirioni O; Petroni S; Scalise G
    Eur J Clin Microbiol Infect Dis; 1994 Apr; 13(4):315-8. PubMed ID: 8070438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel insertion sequence, ISPA26, in oprD of Pseudomonas aeruginosa is associated with carbapenem resistance.
    Evans JC; Segal H
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3776-7. PubMed ID: 17682099
    [No Abstract]   [Full Text] [Related]  

  • 13. Outbreak of Pseudomonas aeruginosa producing IMP-9-type metallo-beta-lactamase in Guangzhou, China.
    Chao Z; Xiao-Feng W; Dan-Hong S; Jin-Ping Y; Nan-Shan Z
    Int J Antimicrob Agents; 2008 Oct; 32(4):363-5. PubMed ID: 18619819
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.
    Zhou XY; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1387-9. PubMed ID: 8328794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of superinhibitory levels of imipenem and amikacin singly or in combination on Pseudomonas aeruginosa].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1997 Dec; 46(4):155-7. PubMed ID: 9471306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to imipenem in Pseudomonas aeruginosa.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1995 Dec; 36(6):1037-41. PubMed ID: 8821603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. beta-Lactamase induction by N-formimidoylthienamycin.
    Grappel SF; Giovenella AJ; Newman DJ; Nisbet LJ
    J Antibiot (Tokyo); 1984 Sep; 37(9):1101-2. PubMed ID: 6438041
    [No Abstract]   [Full Text] [Related]  

  • 18. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
    Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
    J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates.
    Giakkoupi P; Tzouvelekis LS; Daikos GL; Miriagou V; Petrikkos G; Legakis NJ; Vatopoulos AC
    J Clin Microbiol; 2005 Jan; 43(1):494-6. PubMed ID: 15635025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.